Altimmune Inc (ALT)

[catchmeifyoucan]

Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.

09:27 AM ET 4/11/19 | GlobeNewswire



Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.

Dr. Sybil Tasker to present on April 16 at 12:55pm Eastern Time

GAITHERSBURG, Md., April 11, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced an oral presentation at the World Vaccine Congress being held in Washington D.C. on April 14-17, 2019. The presentation will take place on April 16, 2019 at the Renaissance Washington, DC Downtown Hotel at 12:55pm Eastern Time.

Dr. Sybil Tasker, Chief Medical Officer of Altimmune, will present data from the Company's Phase 2 study and the recently completed Phase 2 extension study for NasoVAX. The Phase 2 data showed that NasoVAX was well-tolerated and highly immunogenic, demonstrating 100% seroprotection at two of the three dose levels studied. Data from the extension study demonstrated that the immunogenic responses were durable with 100% of the evaluated subjects remaining seroprotected, and the seroconversion rate remained unchanged for more than one year after vaccination. Durable responses on the order of one year are not expected from current injected influenza vaccines and suggest that the immune response induced by NasoVAX could be protective for the duration of a long flu season.